Both authors are affiliated with the Orbital and Ophthalmic Plastic Surgery Division, Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California.
Dermatol Surg. 2021 May 1;47(5):658-665. doi: 10.1097/DSS.0000000000002928.
The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product.
To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products.
Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting.
The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products.
Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.
2008 年，FDA 批准了比马前列素眼药水 0.03%用于治疗睫毛稀疏症。消费者仍然担心该产品可能存在副作用。
确定与前列腺素睫毛生长产品使用相关的安全信息差距。
使用 PubMed、Embase 和 Nexis Uni 数据库进行文献检索，没有对出版物日期、语言或研究环境进行限制。
关于比马前列素治疗睫毛稀疏症的文献主要由行业赞助的临床试验组成。研究设计选择在我们对这些产品临床安全性的理解上造成了差距。
由于研究设计选择，比马前列素用于睫毛生长的临床试验可能系统地低估了药物应用不适和前列腺素相关眶周病的发生率。虹膜色素沉着增加的风险仍未得到充分研究。因此，需要不断教育和监测选择使用这些产品的患者。
